MarketInOut Stock Screener Log In | Sign Up
 

Immunovant Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 07/13/2026 16:00
Immunovant Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8,152.82 mln
Float78.74 mln
Earnings Date08/12/2026

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

46.47
Attractive

Relative Strength

42 / 100
Slightly lagging

Debt / Equity

0.00
Debt-free

ROE

-68.80
Deeply negative

Dividend Yield

0.00%
No dividend

Business Description

Immunovant is a New York-based medical research company focused on developing new treatments for autoimmune conditions, where the immune system mistakenly attacks the body. The company is working on two experimental drugs targeting a range of serious diseases, including rheumatoid arthritis, lupus, and several rare neurological and eye conditions. Founded in 2018, Immunovant operates as part of Roivant Sciences.

Key Fundamentals

EPS-2.77
ROE-68.80
ROIC-2,870
ROA-62.73
EBITDA, mln-533
EV / EBITDA-13.28
EV / EBIT-13.27

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price46.47
Short Ratio10.32
Short % of Float19.82

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.26% 76 / 100   
1 Month 24.12% 94 / 100   
2 Months 57.96% 94 / 100   
6 Months 47.09% 92 / 100   
1 Year 121% 95 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us